Cartesian Therapeutics (RNAC) announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis. Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy product candidate targeting B-cell maturation antigen. Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living score of three points or more at Month 4 compared to placebo.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho
- Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising mRNA-Based CAR-T Developments and Strategic Clinical Advancements
- Promising Potential of Cartesian Therapeutics’ Descartes-08 Therapy Drives Buy Rating
- Cartesian Therapeutics Reports Q1 2025 Financial Results
- Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue